nVerses Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,141
Closed -$275K – 128
2026
Q2
$275K Buy
+1,141
New +$250K 0.42% 70
2024
Q4
– Sell
-2,600
Closed -$290K – 433
2024
Q3
$290K Buy
+2,600
New +$285K 0.13% 248

Other funds holding JAZZ

nVerses Capital's JAZZ Position: Q3 2026 in Review

nVerses Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2026, closing a stake of 1,141 shares — an estimated $275K sold.

nVerses Capital first reported a position in JAZZ in Q3 2024 and held it in 2 quarters. The position peaked at $290K in Q3 2024. 670 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • nVerses Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • nVerses Capital sold 1,141 Jazz Pharmaceuticals shares in Q3 2026, an estimated $275K.
  • nVerses Capital first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • nVerses Capital's Jazz Pharmaceuticals position peaked at $290K in Q3 2024.
  • 670 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on nVerses Capital's 13F filing for Q3 2026.